CoChat
Sign Up
Cited by 46Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years

Open access
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., Juneja, R.·2016·Diabetes, Obesity and Metabolism
DOI 10.1111/dom.12687PMC PMC5089646
Open this paper in CoChat — free accountOpen PDF

Abstract

Aims: To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in elderly patients (aged ≥65 years) with type 2 diabetes ( T2D ) in six phase III clinical trials. Methods: Patients were grouped into two age groups: ≥65 and <65 years. Pooled analysis for glycated haemoglobin ( HbA1c ) change from baseline, percentage of patients achieving HbA1c targets, and gastrointestinal tolerability were evaluated at 26 weeks for each dulaglutide dose. Change in weight from baseline and rates of hypoglycaemia were evaluated for each individual study. Results: A total of 958 of 5171 (18.5%) patients were aged ≥65 years. The reductions in HbA1c were similar between age groups for dulaglutide 1.5 mg‐treated patients {least squares [ LS ] mean for patients aged ≥65 years: −1.24 [95% confidence interval ( CI ) −1.36, −1.12] and for patients aged <65 years: −1.29 [95% CI −1.38, −1.20]} and for dulaglutide 0.75 mg‐treated patients [ LS mean for patients aged ≥65 years: −1.16 (95% CI −1.29, −1.03) and for patients aged <65 years: −1.10 (95% CI −1.19, −1.01)] at 26 weeks. The percentages of patients who achieved HbA1c targets of <7, <8 or <9% were also similar in the two groups with both dulaglutide doses. Patients aged ≥65 years had similar weight change to patients aged <65 years. Severe hypoglycaemic events were infrequent. A similar incidence of gastrointestinal adverse events was observed in each age group with both dulaglutide doses. Conclusion: Both dulaglutide doses were well tolerated, with similar efficacy in patients with T2D aged ≥65 years to those aged <65 years. Dulaglutide can be considered a safe and effective treatment option for use in older adults.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12687

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. [1]Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047– 1053. 15111519
  2. [3]Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient‐centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140– 149. 25538310
  3. [4]Gregg EW, Yaffe K, Cauley JA et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000; 160: 174– 180. 10647755
  4. [5]Gregg EW, Mangione CM, Cauley JA et al. Diabetes and incidence of functional disability in older women. Diabetes Care 2002; 25: 61– 67. 11772902
  5. [6]Gregg EW, Sorlie P, Paulose‐Ram R et al. Prevalence of lower‐extremity disease in the US adult population > =40 years of age with and without diabetes: 1999‐2000 national health and nutrition examination survey. Diabetes Care 2004; 27: 1591– 1597. 15220233
  6. [8]Menz HB, Lord SR, St George R, Fitzpatrick RC. Walking stability and sensorimotor function in older people with diabetic peripheral neuropathy. Arch Phys Med Rehabil 2004; 85: 245– 252. 14966709
  7. [9]Richardson JK, Thies S, Ashton‐Miller JA. An exploration of step time variability on smooth and irregular surfaces in older persons with neuropathy. Clin Biomech (Bristol, Avon) 2008; 23: 349– 356. PMC2277078 18035458
  8. [10]Richardson JK, Thies SB, DeMott TK, Ashton‐Miller JA. Gait analysis in a challenging environment differentiates between fallers and nonfallers among older patients with peripheral neuropathy. Arch Phys Med Rehabil 2005; 86: 1539– 1544. 16084805
  9. [11]Halter JB, Morrow LA. Use of sulfonylurea drugs in elderly patients. Diabetes Care 1990; 13: 86– 92.
  10. [12]American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care 2012; 35(Suppl. 1): S11– 63. 22187469 PMC3632172
  11. [13]Sinclair AJ, Paolisso G, Castro M, Bourdel‐Marchasson I, Gadsby R, Rodriguez ML. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011; 37 Suppl. 3: S27– S38. 22183418
  12. [14]Bryan J, Crane A, Vila‐Carriles WH, Babenko AP, Aguilar‐Bryan L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des 2005; 11: 2699– 2716. 16101450
  13. [16]Ober SK, Watts S, Lawrence RH. Insulin use in elderly diabetic patients. Clin Interv Aging 2006; 1: 107– 113. 18044107 PMC2695160
  14. [17]Bode B. Liraglutide: a review of the first once‐daily GLP‐1 receptor agonist. Am J Manag Care 2011; 17: S59– S70. 21517658
  15. [18]Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract 2012; 66: 1021– 1032. 22925173 PMC3506736
  16. [19]Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J. Efficacy and safety of lixisenatide in elderly (>/=65 years old) and very elderly (>/=75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. Diabetes Metab Res Rev 2015; 31: 204– 211. 25115916
  17. [20]Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP‐4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes 2013; 6: 161– 170. 23650450 PMC3639752
  18. [21]Barrington P, Chien JY, Showalter HD et al. A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 426– 433. 21251178
  19. [22]Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434– 438. 21251179
  20. [23]Matfin G, Van Brunt K, Zimmermann AG, Threlkeld R, Ignaut DA. Safe and effective use of the once weekly dulaglutide single‐dose pen in injection‐naive patients with type 2 diabetes. J Diabetes Sci Technol 2015; 9: 1071– 1079. 25901022 PMC4667342
  21. [25]Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD‐3). Diabetes Care 2014; 37: 2168– 2176. 24842985
  22. [27]Blonde L, Jendle J, Gross J et al. Once‐weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD‐4): a randomised, open‐label, phase 3, non‐inferiority study. Lancet 2015; 385: 2057– 2066. 26009229
  23. [29]Wysham C, Blevins T, Arakaki R et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD‐1). Diabetes Care 2014; 37: 2159– 2167. 24879836
  24. [30]Dungan KM, Povedano ST, Forst T et al. Once‐weekly dulaglutide versus once‐daily liraglutide in metformin‐treated patients with type 2 diabetes (AWARD‐6): a randomised, open‐label, phase 3, non‐inferiority trial. Lancet 2014; 384: 1349– 1357. 25018121
  25. [31]Fonseca V, McDuffie R, Calles J et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care 2013; 36: 2162– 2168. 23412077 PMC3714487
  26. [32]Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 1992; 15: 75– 80. 1737544
  27. [33]Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes >/=65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother 2011; 9: 423– 433. 22055210
  28. [35]Crane PK, Walker R, Larson EB. Glucose levels and risk of dementia. N Engl J Med 2013; 369: 1863– 1864. 24195563
  29. [36]Dominguez LJ, Paolisso G, Barbagallo M. Glucose control in the older patient: from intensive, to effective and safe. Aging Clin Exp Res 2010; 22: 274– 280. 19934622

Cited by

Sorted by citations

Authors
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R.
Affiliations
  • Indiana University Indianapolis (US)
  • Providence Medical Group Terre Haute IN USA
  • Eli Lilly (Canada) (CA)
  • Eli Lilly (United States) (US)
Corresponding author
Juneja, R.
ORCID
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-06-07
Volume
18
Issue
8
Pages
820-828
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/dom.12687
PMC
PMC5089646
OpenAlex
W2466620119
Cited by
46
References
6
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 7 · 2019: 7 · 2018: 6 · 2017: 3
FWCI
5.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
dulaglutide, type 2 diabetes, elderly patients, age differences, HbA1c, HbA1c targets, gastrointestinal adverse effects, hypoglycemia, weight change, GLP-1 receptor agonists, dose comparison
MeSH terms
Age Factors, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diarrhea, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Nausea, Recombinant Fusion Proteins, Least-Squares Analysis, Treatment Outcome, Clinical Trials, Phase III as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review